Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Scott F. Huntington et al.|Blood|2020Cited by 318
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P. Shah, Kristina M. Gregory, Ravi Bhatia et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 116
Overcoming adaptive therapy resistance in AML by targeting immune response pathwaysKatelyn Melgar, Daniel T. Starczynowski, Morgan M. Walker et al.|Science Translational Medicine|2019Cited by 88
CML and the WHO: Why?Ellin Berman, Brian Druker, Neil P. Shah et al.|Journal of Clinical Oncology|2023Cited by 14
Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed <i>FLT3</i> Mutated AMLSelina M. Luger, Mark R. Litzow, Li Chen et al.|Blood|2024Cited by 7